Previous study [45] demonstrated that dexamethasone, an anti-inflammatory agent, ameliorated biochemical and histologic AKI after 24 h by a receptor-dependent, nongenomic signaling involving the MEK-ERK 1/2 pathway. This evidence concerns the gene MAP2K7 and acute kidney injury.